EGFR wild-type

This first comprehensive analysis of PD-L1 prevalence in patients with NSCLC in Jordan demonstrates a relatively high prevalence of both PD-L1 positivity (≥1%) and high expression (≥50%) compared with reported data from other regions. Distinct molecular associations were observed, with higher PD-L1 expression in ALK-rearranged and EGFR wild-type tumors. These findings underscore the need for prospective and multicenter studies to further identify the biologic and clinical implications of PD-L1 expression in Jordanian patients with NSCLC.

Dynamic changes in serum VEGF levels were associated with treatment response; however, these findings should be interpreted with caution due to the retrospective design and absence of a control group. Further well-designed prospective controlled studies are warranted to validate these observations.

Compounds JRC-2 and JRC-6 exhibited potent antiproliferative effects against MCF-7 breast cancer cells, with IC50 values of 4.59 ± 0.23 µM and 4.01 ± 0.14 µM, respectively, outperforming erlotinib (IC50 = 9.39 ± 0.16 µM). Notably, JRC-6 displayed microtubule-stabilising activity comparable to that of paclitaxel and induced ROS generation, mitochondrial membrane depolarisation, and G2/M phase cell cycle arrest. Molecular docking and molecular dynamics simulations confirmed stable binding of compounds at the EGFR ATP-binding site and the tubulin taxol-binding site.

NGS-based liquid biopsy identified actionable and resistance-associated mutations in 25% of advanced NSCLC patients in this Turkish Black Sea cohort. Total cfDNA concentration correlated with metastatic burden. The detection of KRAS G12C and EGFR T790M variants supports the complementary clinical utility of multi-gene plasma ctDNA panels alongside tissue genotyping in personalized treatment decisions, although confirmation in larger prospective cohorts with paired tissue analysis is warranted.

In grade 3 stage IA3 LUAD, the presence of an EGFR mutation was associated with a poorer prognosis compared with EGFR wild type. These findings underscore the potential need to explore tailored adjuvant treatment strategies in this subgroup.

P2, N=316, Active, not recruiting, Guangdong Association of Clinical Trials | Recruiting --> Active, not recruiting | N=48 --> 316 | Trial completion date: Jul 2024 --> Aug 2026 | Trial primary completion date: Aug 2020 --> May 2026

However, intrinsic and acquired resistance to EGFR-targeted antibody therapies such as cetuximab remains a major limitation to achieving broad and durable treatment responses...Anti-tumor activity was additionally demonstrated in an EGFR-expressing CT-26 syngeneic tumor model in vivo. Collectively, these findings define a promising therapeutic strategy to overcome resistance to current EGFR-targeted therapies and provide a strong rationale for the development of next-generation T-cell - redirecting therapies in patients with EGFR-positive malignancies.

MRI and clinical features may provide the ability to noninvasively distinguish between SCLC and NSCLC and between AD and SCC, as well as to partially indicate EGFR status. DWI hyperintensity without CE-T1WI enhancement might serve as a key subtype-specific feature that could aid in clinical decision-making.

This case demonstrated successful reversal of severe immune-related cardiac toxicity in a patient with advanced squamous cell lung cancer with high PD-L1 expression through personalized, precise, and multidisciplinary team diagnosis and treatment, achieving prolonged overall survival. Furthermore, this case suggested that anti-angiogenic therapy (anlotinib) can be safely administered as subsequent treatment for lung squamous cell carcinoma following recovery from severe immune-related cardiotoxicity.

P1/2, N=118, Not yet recruiting, Multitude Therapeutics Inc.

P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2027 --> Mar 2027

Initial data suggest that BLU-451 is an active molecule. Further evaluation of the safety profile and pharmacokinetic properties of BLU-451 is needed.